Aleph-7

Pharmaceutical compound From Wikipedia, the free encyclopedia

Aleph-7, or ALEPH-7, also known as 4-propylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1] It is one of the Aleph series of compounds.[1]

Other namesALEPH-7; DOT-7; 4-Propylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-propylthioamphetamine; 4-PrS-DMA
ATC code
  • None
Quick facts Clinical data, Other names ...
Aleph-7
Clinical data
Other namesALEPH-7; DOT-7; 4-Propylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-propylthioamphetamine; 4-PrS-DMA
Routes of
administration
Oral[1]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Monoamine oxidase inhibitor; Reversible inhibitor of MAO-A
ATC code
  • None
Pharmacokinetic data
Duration of action15–30 hours[1]
Identifiers
  • 1-(2,5-dimethoxy-4-propylsulfanylphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23NO2S
Molar mass269.40 g·mol−1
3D model (JSmol)
  • CCCSC1=C(C=C(C(=C1)OC)CC(C)N)OC
  • InChI=1S/C14H23NO2S/c1-5-6-18-14-9-12(16-3)11(7-10(2)15)8-13(14)17-4/h8-10H,5-7,15H2,1-4H3
  • Key:XHWDHFUBCVWXDZ-UHFFFAOYSA-N
Close

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-7's dose as 4 to 7 mg orally and its duration as 15 to 30 hours.[1] The effects of Aleph-7 have been reported to include strangeness, slight visual changes, intense but difficult to describe altered states of consciousness, everything feeling "preprogrammed", emotional changes, negative reactions, unwillingness to take the drug again, relaxation, and paresthesia, among others.[1] It was said to produce a "Beth state", defined as a state of uncaring, anhedonia, and emotionlesssness.[1] Many other drugs are also said to have a touch of such a state, but Aleph-7 to have more of it than most.[1]

It is a potent agonist of the serotonin 5-HT2A receptor, with an EC50Tooltip half-maximal effective concentration of 2.2 to 7.6 nM and an EmaxTooltip maximal efficacy of 116 to 189%.[2] The drug is also a weak monoamine oxidase inhibitor (MAOI), specifically a reversible inhibitor of MAO-A (RIMA), with an IC50Tooltip half-maximal inhibitory concentration of 2.4 μM.[3][4]

The chemical synthesis of Aleph-7 has been described.[1]

Aleph-7 was first described in the scientific literature by Shulgin in 1981.[5][6] Subsequently, it was described in greater detail by Shulgin PiHKAL in 1991.[1] The drug was encountered as a novel designer drug in Europe in 2005.[7] It is a controlled substance in Canada under phenethylamine blanket-ban language.[8]

See also

References

Related Articles

Wikiwand AI